| Literature DB >> 32745361 |
Emma K Grant1,2, David J Fallon1,2, Michael M Hann1, Ken G M Fantom1, Chad Quinn3, Francesca Zappacosta3, Roland S Annan3, Chun-Wa Chung1, Paul Bamborough1, David P Dixon1, Peter Stacey1, David House1, Vipulkumar K Patel1, Nicholas C O Tomkinson2, Jacob T Bush1.
Abstract
Advances in genomic analyses enable the identification of new proteins that are associated with disease. To validate these targets, tool molecules are required to demonstrate that a ligand can have a disease-modifying effect. Currently, as tools are reported for only a fraction of the proteome, platforms for ligand discovery are essential to leverage insights from genomic analyses. Fragment screening offers an efficient approach to explore chemical space. Presented here is a fragment-screening platform, termed PhABits (PhotoAffinity Bits), which utilizes a library of photoreactive fragments to covalently capture fragment-protein interactions. Hits can be profiled to determine potency and the site of crosslinking, and subsequently developed as reporters in a competitive displacement assay to identify novel hit matter. The PhABit platform is envisioned to be widely applicable to novel protein targets, identifying starting points in the development of therapeutics.Keywords: covalent; drug discovery; inhibitors; photoaffinity; proteins
Mesh:
Substances:
Year: 2020 PMID: 32745361 DOI: 10.1002/anie.202008361
Source DB: PubMed Journal: Angew Chem Int Ed Engl ISSN: 1433-7851 Impact factor: 15.336